Megan Barnet

attempting to strike a balance between motherhood, medical oncology, immunology research and *life (*stuff that happens in between)

[Megan Barnet @meg_barnet]

Memorable eve at the Lachlan Kean Foundation Ball raising awareness for early onset colorectal cancer @GarvanInstitute @kinghorncancer @GICancer

Bowel cancer screening now starts age 45 or 40 if you ask your GP. Pay attention to symptoms at any age - this disease is changing

[Megan Barnet @meg_barnet]

@gjmccaughan @SVHSydney @kinghorncancer @annabelcrabb Great night raising awareness for early onset colorectal cancer and valuable funds for research with @GICancer !

[Megan Barnet @meg_barnet]

Heading home to my very own #messehaus. Thanks #ESMOGI24 @MacarullaTeresa @DucreuxMichel and Prof Eric Van Cutsem for a fantastic program and amazing week in Munich! @JiaJennyLiu @kinghorncancer

[Megan Barnet @meg_barnet]

TOPAZ-1 update at mFU 41m - OS HR strengthened 0.8 —> 0.74, if have a CR/PR 1/3 alive at 3y vs 16% chemo. 17% ‘long term’ survivors, across all subgroups iCCA/eCCA/GBC/ROW/PDL1 #ESMOGI24

[Megan Barnet @meg_barnet]

Promising ORR 32% in CLDN18.2 mod/high (90% cohort) heavily pre treated pt w/ G/GOJ. Similar responses, less N/V than other CLDN18.2 Abs @JiaJennyLiu @kinghorncancer #ESMOGI24

[Megan Barnet @meg_barnet]

@MacarullaTeresa presenting 18m update CD40a mitazalimab + mFFX in metPDAC. ORR 42%, med DoR 12.6m(!), 1y PFS 55%. Compares well w FFX ORR 31% 1y PFS 12%. Mita added minimal liver tox / no CRS. Progressing to Ph3 #ESMOGI24

[Megan Barnet @meg_barnet]

@D_JafariMD presents NEST1/2 path RR 1st 20 pt (resectable non-met CRC) w/ BOT(next gen anti-CTLA4)/BAL(anti-PD1) - impressive 71% path RR in MSS (12/17), all got surgery despite 10% G3 colitis (-> steroid + infliximab). Signif tox; survival outcomes v SoC important #ESMOGI24

[Megan Barnet @meg_barnet]

Summary ongoing BRAFm mCRC trials w/ @ModestDominik
1L BREAKWATER MSS Ph3 enco/cetux +/CT v CT-bev
1L SEAMARK MSI Ph2 enco/cetux/pembro v pembro
2L SWOG2107 MSS Ph2 enco/cetux v enco/cetux/nivo
3L BRICKET (🦗) Ph2 rechallenge enco/cetux if no alt ctDNA #ESMOGI24

[Megan Barnet @meg_barnet]

Biological rationale of EGFR-MET Bispec Ab Amivantamab w/ @TaberneroJosep; averting met-amplification rel. resistance, inducing ADCC. We will test in 1L Ph3 ORIGAMI-2 trial w/ platinum doublet vs CT/cetux in RAS/BRAFwt L-sided mCRC opening soon👊 @kinghorncancer #ESMOGI24

[Megan Barnet @meg_barnet]

PDAC has more negative trials than any other tumour stream… Trying to find Prof Thomas Seufferlein’s summary slide motivating rather than deflating.
Nal-iri combos underwhelming and not compared to FOLFIRI/mFFX
#ESMOGI24

[Megan Barnet @meg_barnet]

Laurence Zitvogel @GustaveRoussy tour de force microbiome. Meta-anal. AB use -60 to +42d C1 PD1; surge pathogenic bact. post AB down-reg gut checkpoint MadCAM —> exodus immunosupp cells inc Th17 from gut to cancer. PD1 at this point amplifies exodus 🪨/doc/hard place #ESMOGI24

[Megan Barnet @meg_barnet]

Thought provoking talk from @ben_irit on QoL issues in EOCRC, esp paucity of data re: fertility pres. w/ RT + oxali (can’t extrapolate GnRHa from CTX - can worsen problem), cardiovascular tox (CVD 54% CRC survivors v 17% Gen pop), psychosocial, body image, sexual fnc #ESMOGI24

[Megan Barnet @meg_barnet]

KN585 OS (noting EFS/trial stat. neg despite 20m improvement) OS benefit 6% at5yrs. FLOT (v CF) backbone did better (cis poor PD1 partner), but only 20% cohort, clear benefit CPS >10/MSI-H. Appealing option; may solidify w MATTERHORN survival (100% FLOT) @KoheiShitara #ESMOGI24

[Megan Barnet @meg_barnet]

Unsurprising QoL data for TRANSMET, late deviation in favour LT+C v C. Interesting summary from @ChiaraCrem1 re pattern of relapse liver TP (lung dominant) v resection (liver dominant) #ESMOGI24

[Megan Barnet @meg_barnet]

RV of rationale for differing OS + ongoing pref up-front surgery Asian v Western gastric w/ Prof Sun Young Rha @yonsei_u: 5yOS >60 v 25% ! Screening program/more early disease, long-standing D2 dissection SoC, diff histo path (non-cardia > cardia). #ESMOGI24

[Megan Barnet @meg_barnet]

A reminder from Prof Karin Haustermans of why rad oncs dislike PROSPECT (…aside from inclusion of patients who didn’t need NA tx) #ESMOGI24

[Megan Barnet @meg_barnet]

Masterclass in ctDNA from @JeanneTie at #ESMOGI24. Efforts to improve sensitivity inc: track more muts (WES vs panel), reduce BG noise (seq PBMCs, technical improvements), increase cf DNA input (how much blood ethically ok w serial collections) #aussiesonthepodium

[Megan Barnet @meg_barnet]

Further consideration of ESOPEC w Ian Chau - FLOT in Germany > FLOT rest-of-world? pCR FLOT4, DANTE, ESOPEC 15-17% vs others ~7% #ESMOGI24

[Megan Barnet @meg_barnet]

Great summary from Ryan Corcoran @MGHCancerCenter re targeting RAS. Similar single agent ORR G12Cinh PDAC compared w/ NSCLC, vs CRC which improves w/ addition anti-EGFR. Supports KRAS good target in PDAC …just need to progress in G12D #ESMOGI24

[Jacqueline Tearle @JacTearle]

Thrilled to lead this exciting project deciphering young-onset colorectal cancer alongside @meg_barnet @KylieReneeJames and Dr Subo Thavaneswaran 🥳